Your browser is no longer supported. Please, upgrade your browser.
MacroGenics, Inc.
Index- P/E- EPS (ttm)-2.46 Insider Own0.20% Shs Outstand61.17M Perf Week-9.41%
Market Cap790.18M Forward P/E- EPS next Y-2.79 Insider Trans- Shs Float57.52M Perf Month-24.66%
Income-146.20M PEG- EPS next Q-0.80 Inst Own96.50% Short Float4.73% Perf Quarter-34.59%
Sales116.00M P/S6.81 EPS this Y21.60% Inst Trans-0.21% Short Ratio5.84 Perf Half Y-50.70%
Book/sh4.76 P/B2.67 EPS next Y10.20% ROA-35.80% Target Price37.62 Perf Year-43.64%
Cash/sh4.81 P/C2.64 EPS next 5Y- ROE-46.50% 52W Range12.81 - 36.48 Perf YTD-20.81%
Dividend- P/FCF- EPS past 5Y-31.30% ROI-44.30% 52W High-65.16% Beta2.08
Dividend %- Quick Ratio4.80 Sales past 5Y0.80% Gross Margin98.50% 52W Low-0.78% ATR1.01
Employees370 Current Ratio4.90 Sales Q/Q-14.20% Oper. Margin- RSI (14)27.85 Volatility6.77% 6.46%
OptionableYes Debt/Eq0.00 EPS Q/Q-30.60% Profit Margin- Rel Volume0.92 Prev Close12.90
ShortableYes LT Debt/Eq0.00 EarningsNov 02 AMC Payout- Avg Volume465.55K Price12.71
Recom1.70 SMA20-17.05% SMA50-24.97% SMA200-45.38% Volume427,140 Change-1.47%
Nov-17-21Resumed Guggenheim Buy $30
Oct-19-21Initiated JMP Securities Mkt Outperform $39
Oct-15-21Resumed BTIG Research Buy $50
Apr-26-21Resumed Credit Suisse Outperform $37
Mar-12-21Upgrade Barclays Underweight → Overweight $14 → $40
Dec-22-20Resumed H.C. Wainwright Buy $36
Aug-03-20Downgrade Citigroup Buy → Neutral $25 → $26
Jun-01-20Upgrade Guggenheim Neutral → Buy
May-26-20Reiterated H.C. Wainwright Buy $22 → $40
Mar-04-20Initiated Barclays Underweight $8
Dec-19-19Initiated Cantor Fitzgerald Overweight
Dec-18-19Initiated Cantor Fitzgerald Overweight
Nov-21-19Downgrade Morgan Stanley Equal-Weight → Underweight $17 → $6
Nov-20-19Resumed Guggenheim Neutral
May-03-19Upgrade Wedbush Neutral → Outperform $26
Apr-12-19Initiated Guggenheim Neutral
Feb-07-19Upgrade Citigroup Sell → Buy
Feb-07-19Downgrade Wedbush Outperform → Neutral
Feb-06-19Upgrade Raymond James Underperform → Mkt Perform
Feb-04-19Downgrade Citigroup Neutral → Sell $10
Dec-28-21 09:38AM  
Dec-23-21 12:38PM  
Dec-21-21 09:38AM  
Dec-14-21 06:29PM  
Dec-08-21 09:38AM  
Nov-03-21 04:01PM  
Nov-02-21 05:15PM  
Oct-26-21 04:30PM  
Oct-25-21 09:12AM  
Oct-15-21 10:53AM  
Oct-01-21 07:43AM  
Sep-22-21 01:10PM  
Sep-17-21 08:48AM  
Sep-16-21 12:18PM  
Sep-12-21 07:00PM  
Sep-10-21 06:51AM  
Sep-09-21 06:57PM  
Sep-08-21 04:10PM  
Sep-07-21 05:06PM  
Sep-02-21 04:30PM  
Aug-09-21 04:39AM  
Aug-05-21 04:30PM  
Jul-30-21 10:31PM  
Jul-29-21 06:25PM  
Jul-22-21 04:05PM  
Jul-06-21 10:20AM  
Jun-18-21 07:45PM  
Jun-17-21 02:49PM  
Jun-16-21 05:35PM  
Jun-14-21 08:25PM  
Jun-12-21 04:31PM  
Jun-08-21 05:35PM  
May-25-21 11:00AM  
May-20-21 11:52AM  
May-19-21 05:05PM  
May-07-21 01:55AM  
Apr-30-21 02:31AM  
Apr-29-21 05:35PM  
Apr-24-21 08:47AM  
Apr-22-21 12:33PM  
Apr-19-21 04:30PM  
Apr-10-21 08:30AM  
Apr-09-21 06:30AM  
Mar-15-21 03:15AM  
Mar-02-21 11:43PM  
Feb-26-21 07:30AM  
Feb-25-21 04:01PM  
Feb-18-21 04:30PM  
Feb-11-21 04:30PM  
Feb-08-21 07:30AM  
Jan-25-21 03:34PM  
Jan-11-21 08:45AM  
Dec-22-20 11:52PM  
Dec-18-20 07:30AM  
Dec-17-20 03:47PM  
Dec-16-20 08:15PM  
Dec-13-20 09:14AM  
Dec-07-20 07:30AM  
Dec-06-20 01:00PM  
Dec-01-20 08:08AM  
Nov-30-20 04:30PM  
Nov-09-20 05:00PM  
Nov-06-20 08:06AM  
Nov-05-20 04:33AM  
Nov-04-20 06:05PM  
Oct-28-20 04:30PM  
Oct-15-20 04:30PM  
Oct-05-20 11:19AM  
Sep-23-20 07:15AM  
Sep-22-20 04:30PM  
Sep-21-20 07:30AM  
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B A CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH TARGET N V10% OwnerNov 19Buy18.50200,0003,700,3207,275,564Nov 23 12:29 PM
Bonvini EzioSr VP, Research & CSONov 16Option Exercise16.002,54040,640111,090Nov 16 05:30 PM
BIOTECH TARGET N V10% OwnerSep 29Buy20.47100,0002,047,4607,075,564Sep 30 03:09 PM
BIOTECH TARGET N V10% OwnerSep 28Buy20.64100,0002,063,9606,975,564Sep 30 03:09 PM
BIOTECH TARGET N V10% OwnerSep 17Buy19.93200,0003,986,6806,875,564Sep 20 12:21 PM
BIOTECH TARGET N V10% OwnerSep 16Buy20.94400,0008,376,8006,675,564Sep 20 12:21 PM
Spitznagel ThomasSr VP, BPD & ManufacturingJul 16Option Exercise7.515,00037,5505,000Jul 20 05:09 PM
Spitznagel ThomasSr VP, BPD & ManufacturingJul 16Sale25.015,000125,0500Jul 20 05:09 PM
Bonvini EzioSr VP, Research & CSOJun 24Option Exercise16.7326,076436,337108,550Jun 28 08:14 PM
BIOTECH TARGET N V10% OwnerJun 21Buy21.7475,0001,630,1706,275,564Jun 23 01:33 PM
BIOTECH TARGET N V10% OwnerJun 16Buy21.04100,0002,104,3906,200,564Jun 17 02:54 PM
BIOTECH TARGET N V10% OwnerJun 15Buy20.5375,0001,539,6156,100,564Jun 17 02:54 PM
Spitznagel ThomasSr VP, BPD & ManufacturingApr 15Option Exercise7.515,00037,5505,000Apr 19 06:37 PM
Spitznagel ThomasSr VP, BPD & ManufacturingApr 15Sale30.915,000154,5500Apr 19 06:37 PM
Karrels JamesSVP, CFO and SecretaryMar 22Sale33.0015,000495,000143,460Mar 24 05:07 PM
Bonvini EzioSr VP, Research & CSOMar 22Sale32.003,917125,34479,890Mar 24 05:04 PM
Peters Jeffrey StuartGeneral CounselMar 08Option Exercise11.5021,749250,11421,749Mar 09 07:55 PM
Peters Jeffrey StuartGeneral CounselMar 08Sale26.5021,749576,3480Mar 09 07:55 PM
Karrels JamesSVP, CFO and SecretaryJan 28Option Exercise1.426,0008,490158,460Jan 29 05:10 PM